Our activities as a dedicated private equity healthcare investor date back to the late 1980s. At that time, providing start-up and growth capital to innovative healthcare companies was not commonplace; in fact, we were one of the first to assume this role. Over time, we have grown to become the leader in this field in Europe. We have raised more than € 2 billion through various funds that target drug development and medical technology.
Currently we manage four different fund types:
LSP 6: a closed-end private equity fund investing in early-to late stage drug development and medical technology companies;
LSP HEF 2 (Health Economics Fund): a closed-end private equity fund investing in late-stage medical technology companies with a health and economic benefit;
LSP Dementia: a closed-end private equity fund investing in innovative companies focussing on neurodegenerative diseases and dementia;
LSP Public: an open-ended fund investing in healthcare companies listed on a stock exchange. The fund itself is listed on Euronext as LSP Life Sciences Fund with Bloomberg ticker LSP NA and ISIN Code NL0009756394.
More information on each of these funds including their portfolio of investments can be found by clicking on one of the boxes below.